United Kingdom Cancer Biopsy Market Size, Share By Type (Tissue Biopsies, Surgical Biopsies, Needle Biopsies, Core Needle Biopsy (CNB), Fine Needle Aspiration (FNA), Liquid Biopsies, and Others), By Application (Lung Cancer, Prostate Cancer, Blood Cancer, Ovarian Cancer, Liver Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, Skin Cancer, Kidney Cancer, Pancreatic Cancer, and Others), United Kingdom Cancer Biopsy Market Insights, Industry Trend, Forecasts to 2035

United Kingdom Cancer Biopsy Market Insights Forecasts to 2035

• United Kingdom Cancer Biopsy Market Size 2024: USD 1753.6 Million
• United Kingdom Cancer Biopsy Market Size 2035:  USD 4529.7 Million
• United Kingdom Cancer Biopsy Market CAGR 2024: 9.01%
• United Kingdom Cancer Biopsy Market Segments: Type and Application

The United Kingdom cancer biopsy market is a steadily growing segment of the oncology diagnostics industry. The market includes tissue biopsy methods which are core needle and excisional and incisional biopsies together with liquid biopsies, image-guided biopsy methods, fine needle aspiration and advanced molecular genetic testing services. The solutions enable NHS and private oncology diagnostic pathways to achieve early detection, precise tumor identification and tailored treatment development. The market's primary drivers consist of increasing cancer cases in the UK, heightened public understanding of early cancer detection, the government-supported cancer screening, rapid diagnostic center programs, progress in less invasive, exact biopsy technologies and growing digital health platform partnerships with pathology services.

In April 2023, the NHS Pharmacy Contraception Service in England enables community pharmacies to supply oral contraception. Expanded in December 2023 to include initiation, and further widened in 2025 to cover emergency contraception and pharmacy technicians, improving access and easing GP workload.

The United Kingdom market for cancer biopsy procedures has considerable growth potential because cancer incidence increases and early detection methods gain importance and people require precise diagnostic results within short timeframes. The public now understands cancer screening better and the NHS provides quicker referral pathways which create increased need for advanced biopsy solutions. The latest medical advancements introduce minimally invasive image-guided biopsy methods and liquid biopsy technologies which enable early cancer detection, cancer monitoring, AI-powered pathology analysis and genomic profiling technologies. Digital pathology platforms and integrated laboratory information systems create faster diagnostic results and improved operational efficiency in the medical field.

Market Dynamics of the United Kingdom Cancer Biopsy Market

The UK cancer biopsy market is driven by strong government and NHS initiatives aimed at improving early cancer detection, accelerating diagnostic timelines, and enhancing access to oncology services. The NHS England national strategies which include Rapid Diagnostic Centre expansion and cancer screening program development focus on increasing early cancer detection rates while improving patient outcomes. The increasing need for precise and prompt biopsy assessments is being met through multiple programs which include community diagnostic centre funding and nationwide cancer education initiatives and the escalating collaboration between NHS trusts and private diagnostic companies. The various initiatives help to decrease waiting periods while they make image-guided and minimally invasive biopsy techniques more accessible throughout the United Kingdom.

The United Kingdom cancer biopsy market faces several restraints, including workforce shortages in pathology, radiology, and oncology services, as well as funding constraints within the public healthcare system. Rising cancer incidence and increasing referral volumes are placing significant pressure on diagnostic laboratories and imaging departments, leading to longer waiting times for biopsy procedures and results.

The future outlook for the United Kingdom cancer biopsy market is positive, supported by continued innovation in oncology diagnostics, strong government focus on early cancer detection, and sustained demand for faster and more accurate diagnostic pathways. The ongoing healthcare reforms together with the national cancer strategies establish a crucial need to decrease diagnostic delays while enhancing patient survival rates throughout the nation. Market expansion is occurring because of progress in minimally invasive biopsy methods, liquid biopsy systems, AI-powered digital pathology and next-generation sequencing technologies. Biopsy testing has become more critical for precision oncology and personalized treatment planning because of increased funding for molecular diagnostics and biomarker testing research.

Market Segmentation

The United Kingdom cancer biopsy market share is classified into type and application.

By Type

The United Kingdom cancer biopsy market is divided by type tissue biopsies, surgical biopsies, needle biopsies, core needle biopsy (CNB), fine needle aspiration (FNA), liquid biopsies, and others. Among these, the tissue biopsies segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. It is because of the Increased use of advanced imaging guidance (ultrasound, MRI, CT) makes needle-based biopsies highly accurate for targeting tumors.

By Application

The United Kingdom cancer biopsy market is divided by application into lung cancer, prostate cancer, blood cancer, ovarian cancer, liver cancer, colorectal cancer, cervical cancer, breast cancer, skin cancer, kidney cancer, pancreatic cancer, and others. Among these, the breast cancer segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. It is because of the increased adoption of imaging-guided needle biopsies, such as vacuum-assisted biopsy, ensures high precision and less damage to surrounding tissue.

Competitive Analysis

The report offers the appropriate analysis of the key organisations/companies involved within the United Kingdom cancer biopsy market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. 

Top Key Companies in United Kingdom Cancer Biopsy Market

• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Illumina Inc.
• QIAGEN N.V.
• Guardant Health Inc.
• Exact Sciences Corporation
• Bio-Rad Laboratories Inc.
• Agilent Technologies Inc.
• Sysmex Corporation
• Angle PLC.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the United Kingdom, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United Kingdom cancer biopsy market based on the below-mentioned segments:

United Kingdom Cancer Biopsy Market, By Type

• Tissue Biopsies
• Surgical Biopsies
• Needle Biopsies
• Core Needle Biopsy (CNB)
• Fine Needle Aspiration (FNA)
• Liquid Biopsies
• Others

United Kingdom Cancer Biopsy Market, By Application

• Lung Cancer
• Prostate Cancer
• Blood Cancer
• Ovarian Cancer
• Liver Cancer
• Colorectal Cancer
• Cervical Cancer
• Breast Cancer
• Skin Cancer
• Kidney Cancer
• Pancreatic Cancer
• Others